Medicament for therapeutic treatment and/or improvement of sepsis

Abstract

A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient.

What is claimed is: 
     
         1 . A method for therapeutic treatment and/or improvement of sepsis, which comprises the step of administrating thrombomodulin to a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4. 
     
     
         2 . The method according to  claim 1 , which comprises the step of administrating thrombomodulin to a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4 and equal to or less than 1.6. 
     
     
         3 . The method according to  claim 1  or  2 , wherein the patient with severe sepsis is a severe septic patient who is not a septic patient with organ dysfunction limited to the liver or kidney. 
     
     
         4 . The method according to  claim 1  or  2 , which comprises the step of administrating thrombomodulin to a patient with severe sepsis accompanied with one or more organ dysfunctions selected from the group consisting of liver dysfunction, kidney dysfunction, respiratory organ dysfunction, and circulatory organ dysfunction. 
     
     
         5 . The method according to  claim 1  or  2 , which comprises the step of administrating thrombomodulin to a patient with severe sepsis accompanied with one or more organ dysfunctions selected from the group consisting of respiratory organ dysfunction and circulatory organ dysfunction. 
     
     
         6 . The method according to  claim 1  or  2 , wherein the thrombomodulin is a soluble thrombomodulin. 
     
     
         7 . The method according to  claim 1  or  2 , wherein the thrombomodulin is a peptide obtainable from a transformed cell prepared by transfecting a host cell with a DNA coding for the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 11. 
     
     
         8 . The method according to  claim 1  or  2 , wherein the soluble thrombomodulin is a peptide containing the amino acid sequence of (i-1) or (i-2) mentioned below, and said peptide is a peptide having the thrombomodulin activities;
 (i-1) the amino acid sequence of the positions 19 to 516 in the amino acid sequence of SEQ ID NO: 9 or 11, or 
 (i-2) the amino acid sequence of (i-1) mentioned above, further including substitution, deletion or addition of one or more amino acid residues. 
 
     
     
         9 . The method according to  claim 1  or  2 , wherein the thrombomodulin is administered at a dose of 0.005 to 1 mg/kg within 5 minutes by intravenous bolus administration. 
     
     
         10 . The method according to  claim 1  or  2 , wherein sepsis is severe sepsis with coagulopathy.